From the Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Department of Oncology, Odense University Hospital, Odense, Denmark.
Epidemiology. 2020 Jul;31(4):599-603. doi: 10.1097/EDE.0000000000001208.
Procedure codes in the Danish National Patient Registry are used for administrative purposes and are a potentially valuable resource for epidemiologic research. To our knowledge, the validity of antineoplastic procedure codes has only been evaluated in one study.
We randomly extracted a sample of 420 patients in the Southern Region of Denmark with a diagnosis of colorectal cancer and an oncology contact during 2016-2018. Using the medical record as gold standard, we computed the positive predictive value (PPV) and sensitivity of antineoplastic procedure codes recorded in the Danish National Patient Registry.
We identified 2,243 codes for antineoplastic treatments in the registry and 2,299 in the medical records. We confirmed that 213 of 214 patients with registered therapies in the Danish National Patient Registry received therapy, corresponding to a PPV of "any registration" of 1.00 (95% confidence interval [CI] = 0.97, 1.00). Considering single registrations, the overall PPV was 0.95 (95% CI = 0.94, 0.95), and the overall sensitivity was 0.90 (95% CI = 0.89, 0.91). Number of recorded treatments and treatments administered were strongly correlated. Considering the most frequent single antineoplastic regimens, PPV ranged from 0.90 (95% CI = 0.87, 0.92) for capecitabine to 0.98 (95% CI = 0.95, 1.00) for cetuximab, whereas sensitivity ranged from 0.81 (95% CI = 0.75, 0.87) for 5-fluorouracil and irinotecan (FOLFIRI) regimen to 0.97 (95% CI = 0.94, 0.99) for bevacizumab. Analysis per hospital showed the highest validity of registrations at the University Hospital.
The validity of antineoplastic procedure codes in the Danish National Patient Registry is generally high and thus usable for epidemiologic research.
丹麦国家患者登记处的程序代码用于行政目的，是流行病学研究的潜在有价值资源。据我们所知，抗肿瘤程序代码的有效性仅在一项研究中进行了评估。
我们随机抽取了 2016 年至 2018 年期间丹麦南部地区的 420 名结直肠癌诊断和肿瘤学接触患者的样本。使用病历作为金标准，我们计算了丹麦国家患者登记处记录的抗肿瘤程序代码的阳性预测值（PPV）和灵敏度。
我们在登记处发现了 2243 个抗肿瘤治疗代码，在病历中发现了 2299 个。我们确认，在丹麦国家患者登记处接受登记治疗的 214 名患者中有 213 名接受了治疗，这对应于“任何登记”的 PPV 为 1.00（95%置信区间[CI] = 0.97，1.00）。考虑单个登记，总体 PPV 为 0.95（95%CI = 0.94，0.95），总体灵敏度为 0.90（95%CI = 0.89，0.91）。记录的治疗次数和治疗次数之间存在很强的相关性。考虑最常见的单一抗肿瘤方案，PPV 范围从卡培他滨的 0.90（95%CI = 0.87，0.92）到西妥昔单抗的 0.98（95%CI = 0.95，1.00），而敏感性范围从 5-氟尿嘧啶和伊立替康（FOLFIRI）方案的 0.81（95%CI = 0.75，0.87）到贝伐单抗的 0.97（95%CI = 0.94，0.99）。按医院分析显示，大学医院的登记有效性最高。
丹麦国家患者登记处的抗肿瘤程序代码的有效性通常较高，因此可用于流行病学研究。
